I’ve been grappling with a decision I made just last week, and it’s one that reinforces a pattern I’ve seen time and again. A young, eager founder approached me with a startup idea that, on paper, seemed promising. They were passionate, had a well-crafted pitch, and were even backed by a few initial users. Yet, I found myself turning them down, adding them to the 90% of pitches I reject. Why is that? And more importantly, why is this rejection beneficial for both parties involved?
Turning down a startup pitch isn’t about playing the role of a gatekeeper or being overly risk-averse. It’s about being honest—both with myself and the founders who stand before me. In my experience, whether it’s in the fertility clinic or the boardroom, honesty is the cornerstone of any successful endeavor. It’s the same reason I tell my IVF patients when their chances are slim, rather than offering false hope. In the realm of startups, this honesty translates into recognizing when a venture is more of a “vitamin” than an “aspirin”—a nice-to-have rather than a must-have.
Let’s start with the numbers. According to CB Insights, nearly 90% of startups fail within a decade. This statistic isn’t just a number; it’s a reflection of the hard truth that many fail to grasp: ambition isn’t enough. Passion isn’t enough. The real challenge lies in converting that ambition into a sustainable business model. This is a lesson I’ve learned through years of investing and mentoring founders. The allure of a shiny new idea can often blind founders to the harsh realities of the market.
Often, the pitches I receive are full of enthusiasm and energy but lack the clarity of problem-solution fit. Many founders are enamored with their technology or solution without realizing that there’s no real market need. They’re building vitamins in a world that requires aspirins. In one memorable instance, a founder pitched me an app designed to help people choose their outfits by analyzing their wardrobe. It was clever and had a small following. But when asked if users would pay for this service, the founder hesitated. It was a classic case of building something exciting rather than something essential.
So, how do I make these decisions? I apply a method that involves three critical filters: problem clarity, financial discipline, and team dynamics. Each of these elements can make or break a startup, and they guide my decision to invest—or not.
1. Problem Clarity
Ask yourself: Are you solving a real problem? This isn’t about having a flashy demo or a viral marketing campaign. It’s about understanding the pain points of your target audience. If your startup vanished tomorrow, would your customers miss it? If the answer isn’t a resounding “yes,” it’s back to the drawing board. This isn’t just my opinion; it’s backed by data from First Round Capital, which shows that startups lacking a clear market need are unlikely to succeed.
2. Financial Discipline
Numbers never lie. Before chasing growth, understand your unit economics. In the world of IVF, I wouldn’t dream of expanding my clinic without a clear understanding of the costs versus the expected return. Similarly, founders need to understand the lifetime value of their customers, the payback period, and the gross margin per customer. Growth without financial discipline is like building a house on sand; it might look impressive, but it’s bound to collapse.
3. Team Dynamics
A strong team is more than just a collection of smart individuals. It’s about balance—having someone who is customer-focused, someone who watches the numbers, and someone who is deeply invested in solving the problem. I’ve seen startups with brilliant ideas falter because the team couldn’t execute. It’s like having a brilliant treatment plan for a patient but lacking the skilled hands to implement it.
These filters aren’t just theoretical. They’re based on real experiences, both successful and otherwise. Take, for instance, a startup I once mentored that aimed to revolutionize education with AI. The idea was promising, but the execution faltered because the team lacked someone focused on the numbers. They ran out of cash before finding their footing. This experience later informed my belief that AI in education is an aid, not a magic bullet.
But let’s not forget the human element. Turning down a pitch doesn’t mean closing the door forever. It’s an opportunity for founders to refine their ideas, to return with a better understanding of their market and a stronger pitch. It’s a chance for growth and learning. In medicine, we don’t give up on a patient after a failed treatment; we reassess, adjust, and try again. The same principle applies to startups.
Moreover, this rejection process ensures that when I do say “yes,” it’s with conviction and commitment. The startups I choose to back are those that align with my belief in solving real problems and those that demonstrate financial prudence and strong team dynamics. These are the startups that stand a chance of being part of the 10% that succeed.
In conclusion, turning down 90% of startup pitches isn’t about being a naysayer. It’s about being a responsible investor and mentor. It’s about ensuring that when I do invest, it’s in a venture that has the potential to make a real impact. And for the founders, it’s a reminder that rejection isn’t the end; it’s a stepping stone to refining their vision and returning stronger. After all, in both medicine and investing, the path to success is rarely straightforward, but with honesty, clarity, and perseverance, it is achievable.